Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Investigating Beta-Blockers for Inhibiting Corneal Neovascularization in Inflamed Corneas
Author Affiliations & Notes
  • Kyuyeon Han
    Ophthalmology & Visual Sciences, University of Illinois Chicago, Chicago, Illinois, United States
  • Hyungjo Lee
    Ophthalmology & Visual Sciences, University of Illinois Chicago, Chicago, Illinois, United States
  • Hyun Lee
    Pharmaceutical Science, University of Illinois Chicago, Chicago, Illinois, United States
  • Yunjeong Hwang
    Ophthalmology & Visual Sciences, University of Illinois Chicago, Chicago, Illinois, United States
  • Dimitri T Azar
    Ophthalmology & Visual Sciences, University of Illinois Chicago, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Kyuyeon Han None; Hyungjo Lee None; Hyun Lee None; Yunjeong Hwang None; Dimitri Azar None
  • Footnotes
    Support  NIH Grant EY033758
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2915. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kyuyeon Han, Hyungjo Lee, Hyun Lee, Yunjeong Hwang, Dimitri T Azar; Investigating Beta-Blockers for Inhibiting Corneal Neovascularization in Inflamed Corneas. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2915.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This study aims to investigate the potential of beta blockers in reducing corneal neovascularization.

Methods : The cytotoxicity of propranolol, metoprolol, and timolol were assessed using MTS on various endothelial cells, including EOMA, HUVEC, and CPAE.
Tunnel assay and sub-G1 assay via flow cytometry were employed to investigate cell death through apoptosis. Cleaved caspases 7 and PARP were analyzed in beta blockers-treated cells to understand the mechanism of apoptosis.
The effect of beta-blockers on eliminating pre-matured blood vessels in the injured cornea was investigated by topical application ten days after alkali burn.
Histochemistry analysis was used to assess differences in corneal structure and infiltrated immune cells among wild-type, DMSO, and beta blockers-treated corneas.

Results : The tested three beta-blockers exhibited cytotoxicity with an IC50 of 200 μM on various endothelial cells. However, 80% of corneal fibroblasts and epithelial cells survived at 200 μM of beta blockers. Propranolol and metoprolol induced endothelial cell apoptosis through the activation of caspases 7 and PARP as a mechanism of action. After two weeks of treatment, propranolol and timolol halted the growth of pathological blood vessels and eliminated existing blood vessels in alkali burn-induced blood vessels. However, continued blood vessel growth was observed in DMSO and metoprolol-treat cornea. Corneal structure on propranolol and timolol-treated eye exhibited significant recovery from alkali burn, with a thickened epithelium layer and restored stroma layer compared to DMSO and metoprolol-treated cornea. Additionally, a lower number of infiltrated immune cells were identified in propranolol and timolol-treated cornea.

Conclusions : In this study, we conducted a comparative analysis of three beta-blockers based on their selectivity: propranolol and timolol as non-selective beta-blockers, and metoprolol as a selective beta-blocker, aiming to assess their effectiveness in reducing neovascularization in the injured cornea. Our results indicate that non-selective beta-blockers, propranolol, and timolol demonstrated superior performance in reducing pathological blood vessels compared to the selective beta-blocker metoprolol. This led to significant inhibition of inflammation, suggesting the potential of non-selective beta-blockers in effectively addressing neovascularization-associated issues in the injured cornea.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×